Cargando…

LDL apheresis in a woman with severe heterozygous familial hypercholesterolemia. Late, but not too late

Detalles Bibliográficos
Autores principales:	Mickiewicz, Agnieszka, Fijałkowski, Marcin, Rynkiewicz, Andrzej, Raczak, Grzegorz, Gruchała, Marcin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2015
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4697067/ https://www.ncbi.nlm.nih.gov/pubmed/26788101 http://dx.doi.org/10.5114/aoms.2015.56363

Ejemplares similares

Long-term lipoprotein apheresis in the treatment of severe familial hypercholesterolemia refractory to high intensity statin therapy: Three year experience at a lipoprotein apheresis center
por: Mickiewicz, Agnieszka, et al.
Publicado: (2020)

Carotid intima–media thickness (IMT) in patients with severe familial and non-familial hypercholesterolemia: The effect of measurement site on the IMT correlation with traditional cardiovascular risk factors and calcium scores
por: Gałąska, Rafał, et al.
Publicado: (2021)

Case report: lipoprotein apheresis reduces the risk of cardiovascular events and prolongs pregnancy in a woman with severely elevated lipoprotein(a), cardiovascular disease, and a high risk of preeclampsia
por: Marlȩga-Linert, Joanna, et al.
Publicado: (2023)

Myeloperoxidase modulation by LDL apheresis in Familial Hypercholesterolemia
por: Puntoni, Mariarita, et al.
Publicado: (2011)

Aortic Wall Thickness as a Surrogate for Subclinical Atherosclerosis in Familial and Nonfamilial Hypercholesterolemia: Quantitative 3D Magnetic Resonance Imaging Study and Interrelations with Computed Tomography Calcium Scores, and Carotid Ultrasonography
por: Gałąska, Rafał, et al.
Publicado: (2023)

The Impact of Lipoprotein Apheresis on Oxidative Stress Biomarkers and High-Density Lipoprotein Subfractions
por: Mickiewicz, Agnieszka, et al.
Publicado: (2020)

Flaxseed (Linum Usitatissimum L.) Supplementation in Patients Undergoing Lipoprotein Apheresis for Severe Hyperlipidemia—A Pilot Study
por: Kanikowska, Dominika, et al.
Publicado: (2020)

HELP LDL Apheresis Reduces Plasma Pentraxin 3 in Familial Hypercholesterolemia
por: Zanetti, Michela, et al.
Publicado: (2014)

When Do Paediatric Patients with Familial Hypercholesterolemia Need Statin Therapy?(*)
por: Hennig, Matylda, et al.
Publicado: (2017)

Monitoring the Effects of Hypolipidemic Treatment in Children with Familial Hypercholesterolemia in Poland
por: Hennig, Matylda, et al.
Publicado: (2020)

Familial Hypercholesterolemia and Lipoprotein Apheresis
por: Makino, Hisashi, et al.
Publicado: (2019)

Pregnancy in a Woman with Homozygous Familial Hypercholesterolemia Not on Low-Density Lipoprotein Apheresis
por: Fahed, Akl C., et al.
Publicado: (2012)

Impact of selective LDL apheresis on serum chemerin levels in patients with hypercholesterolemia
por: Varga, Viktória E., et al.
Publicado: (2016)

Higher Responsiveness to Rosuvastatin in Polygenic versus Monogenic Hypercholesterolemia: A Propensity Score Analysis
por: Mickiewicz, Agnieszka, et al.
Publicado: (2020)

An update on lipid apheresis for familial hypercholesterolemia
por: Taylan, Christina, et al.
Publicado: (2022)

Long-Term LDL-Apheresis Treatment and Dynamics of Circulating miRNAs in Patients with Severe Familial Hypercholesterolemia
por: Dlouha, Dana, et al.
Publicado: (2023)

Errattum To “When Do Paediatric Patients with Familial Hypercholesterolemia Need Statin Therapy?” [developmental Period Medicine. 2017;21(1):43-50. DOI: 10.34763/devperiodmed.20172101.4350]
por: Hennig, Matylda, et al.
Publicado: (2021)

Usefulness of Lipid Apheresis in the Treatment of Familial Hypercholesterolemia
por: Lui, Matthew, et al.
Publicado: (2014)

Successful Direct Adsorption of Lipoproteins (DALI) Apheresis During Pregnancy in an Omani Woman with Homozygous Familial Hypercholesterolemia
por: Al-Dughaishi, Tamima, et al.
Publicado: (2015)

LDL Apheresis and Lp (a) Apheresis: A Clinician’s Perspective
por: Kayikcioglu, Meral
Publicado: (2021)

Lipoprotein-apheresis reduces circulating microparticles in individuals with familial hypercholesterolemia
por: Connolly, Katherine D., et al.
Publicado: (2014)

Too Late
Publicado: (1860)

Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher
por: Ginsberg, Henry N., et al.
Publicado: (2016)

Effect of LDL cholesterol, statins and presence of mutations on the prevalence of type 2 diabetes in heterozygous familial hypercholesterolemia
por: Climent, Elisenda, et al.
Publicado: (2017)

LDL-Apheresis: Technical and Clinical Aspects
por: Bambauer, Rolf, et al.
Publicado: (2012)

How late is too late for treatment?
por: Reiter, Lawrence T
Publicado: (2023)

Genetics of Hypercholesterolemia: Comparison Between Familial Hypercholesterolemia and Hypercholesterolemia Nonrelated to LDL Receptor
por: Jarauta, Estíbaliz, et al.
Publicado: (2020)

Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia
por: McGowan, Mary P., et al.
Publicado: (2019)

The effect of DALI lipid apheresis in the prognosis of homozygous familial hypercholesterolemia: Seven patients' experience at a DALI apheresis center
por: Bulut, Muhammet, et al.
Publicado: (2020)

Analysis of HDL-microRNA panel in heterozygous familial hypercholesterolemia subjects with LDL receptor null or defective mutation
por: Scicali, Roberto, et al.
Publicado: (2019)

Is OSI too late?
por: Carpenter, B E
Publicado: (1989)

It’s not too late
por: Topol, Eric
Publicado: (2022)

Aortic coarctation – never too late to diagnose, never too late to treat
por: Conti, L, et al.
Publicado: (2017)

How late is too late for nerve transfers
por: Bhatia, Anil
Publicado: (2015)

Systematic Review of Low‐Density Lipoprotein Cholesterol Apheresis for the Treatment of Familial Hypercholesterolemia
por: Wang, Anthony, et al.
Publicado: (2016)

Improvement of oxidative stress status by lipoprotein apheresis in Chinese patients with familial hypercholesterolemia
por: Wen, Jun, et al.
Publicado: (2019)

COVID-19: too little, too late?
por: The Lancet
Publicado: (2020)

Natalizumab for GVHD: too little or too late?
por: Quann, Kevin, et al.
Publicado: (2023)

Genetic screening for homozygous and heterozygous familial hypercholesterolemia
por: Izar, Maria C, et al.
Publicado: (2010)

Aortic valve calcium score in hypercholesterolemic patients with and without low-density lipoprotein receptor gene mutation
por: Gałąska, Rafal, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_f6eqb9rb3sbmbg633n8q4e6sqo